Status:
COMPLETED
Study of a Pandemic Influenza Vaccine
Lead Sponsor:
Seqirus
Conditions:
Influenza
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is the leading candidate to cause the next avian influenza pandemic. This study...
Eligibility Criteria
Inclusion
- Healthy adults
Exclusion
- History of Guillain-Barre syndrome or active neurological disease
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00136331
Start Date
October 1 2005
End Date
November 1 2006
Last Update
July 19 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CMAX, a division of IDT Australia
Adelaide, South Australia, Australia, 5000
2
Murdoch Childrens Research Institute
Melbourne, Victoria, Australia, 3052